This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Men's Health  • Men's Health, Other  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

A. Michael Lincoff, MD

JAMA. 2000;284:1839-1841.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Since the inception of balloon angioplasty in the early 1980s, the field of interventional cardiology has enjoyed explosive growth. It is estimated that more than 1.3 million percutaneous coronary revascularization procedures were performed worldwide in 1999, considerably more than the approximately 700,000 coronary artery bypass graft operations.¹ Important limitations of balloon angioplasty, however, include the risk of uncontrolled plaque disruption, leading to periprocedural coronary occlusion and myocardial infarction, and a 20% to 40% incidence of recurrent narrowing (restenosis) during the 6 to 12 months following successful revascularization.² A variety of new technologies have been developed to overcome these limitations, the most successful of which has been the coronary stent.

A stent is a coil-like metal scaffold implanted within the arterial lumen to provide radial support to the diseased vascular wall. The adoption of stenting into clinical practice was made possible by a crucial evolution in deployment . . . [Full Text of this Article]

Author Affiliations: Department of Cardiology and Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Cleveland, Ohio.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Differences in Prognostic Factors and Outcomes Between Women and Men Undergoing Coronary Artery Stenting
Julinda Mehilli, Adnan Kastrati, Josef Dirschinger, Hildegard Bollwein, Franz-Josef Neumann, and Albert Schömig
JAMA. 2000;284(14):1799-1805.
ABSTRACT | FULL TEXT  

Coronary Artery Stents
Jassim Al Suwaidi, Peter B. Berger, and David R. Holmes, Jr
JAMA. 2000;284(14):1828-1836.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Stent-Assisted Angioplasty of Symptomatic Intracranial Vertebrobasilar Artery Stenosis: Feasibility and Follow-up Results
Kim et al.
Am. J. Neuroradiol. 2005;26:1381-1388.
ABSTRACT | FULL TEXT  

Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting
Koch et al.
J. Lipid Res. 2004;45:2221-2226.
ABSTRACT | FULL TEXT  

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization
Topol et al.
NEJM 2001;344:1888-1894.
ABSTRACT | FULL TEXT